Phase II trial of weekly erlotinib dosing to reduce duodenal polyp burden associated with familial adenomatous polyposis [0.03%]
一项关于每周厄洛替尼给药以减少家族性腺瘤性息肉病相关十二指肠息肉的II期临床试验
N Jewel Samadder,Nathan Foster,Ryan P McMurray et al.
N Jewel Samadder et al.
Importance: Patients with familial adenomatous polyposis (FAP) are at markedly increased risk for duodenal adenomas and cancer. Combination sulindac and erlotinib was previously shown to reduce duodenal polyp burden but w...
Clinical Trial
Gut. 2023 Feb;72(2):256-263. DOI:10.1136/gutjnl-2021-326532 2023
Lysosomal lipid switch sensitises to nutrient deprivation and mTOR targeting in pancreatic cancer [0.03%]
溶酶体脂质转换使胰腺癌更易受到营养剥夺和mTOR靶向治疗的影响
Maria Chiara De Santis,Luca Gozzelino,Jean Piero Margaria et al.
Maria Chiara De Santis et al.
Objective: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease with limited therapeutic options. However, metabolic adaptation to the harsh PDAC environment can expose liabilities useful for therapy. Targetin...
IL-20 subfamily cytokines impair the oesophageal epithelial barrier by diminishing filaggrin in eosinophilic oesophagitis [0.03%]
白细胞介素-20家族细胞因子通过减少丝聚蛋白损害嗜酸细胞性食管炎患者的食管上皮屏障功能
Tanay Kaymak,Berna Kaya,Philipp Wuggenig et al.
Tanay Kaymak et al.
Objective: Disruption of the epithelial barrier plays an essential role in developing eosinophilic oesophagitis (EoE), a disease defined by type 2 helper T cell (Th2)-mediated food-associated and aeroallergen-associated c...
Defining the key intrahepatic gene networks in HCV infection driven by sex [0.03%]
由性别驱动的HCV感染下定义关键的肝内基因网络
Emanuele Marchi,Narayan Ramamurthy,M Azim Ansari et al.
Emanuele Marchi et al.
Objective: The transcriptional response in the liver during HCV infection is critical for determining clinical outcomes. This issue remains relatively unexplored as tissue access to address this at scale is usually limite...
Serological responses to three doses of SARS-CoV-2 vaccination in inflammatory bowel disease [0.03%]
炎症性肠病患者接种三剂SARS-CoV-2疫苗后的血清学反应
Joshua Quan,Christopher Ma,Remo Panaccione et al.
Joshua Quan et al.
British Society of Gastroenterology (BSG) and British Society of Paediatric Gastroenterology, Hepatology and Nutrition (BSPGHAN) joint consensus guidelines on the diagnosis and management of eosinophilic oesophagitis in children and adults [0.03%]
英国胃肠病学会和英国儿科胃肠病、肝病和营养学会关于儿童和成人嗜酸细胞性食管炎诊断与管理的联合共识意见书
Anjan Dhar,Hasan N Haboubi,Stephen E Attwood et al.
Anjan Dhar et al.
Background: Eosinophilic oesophagitis (EoE) is an increasingly common cause of dysphagia in both children and adults, as well as one of the most prevalent oesophageal diseases with a significant impact on physical health ...
Michael Camilleri
Michael Camilleri
Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications [0.03%]
基于新型微环境的肝内胆管癌分类及其治疗意义
Miguel A Martin-Serrano,Benjamin Kepecs,Miguel Torres-Martin et al.
Miguel A Martin-Serrano et al.
Objective: The diversity of the tumour microenvironment (TME) of intrahepatic cholangiocarcinoma (iCCA) has not been comprehensively assessed. We aimed to generate a novel molecular iCCA classifier that incorporates eleme...
Comparison of biochemical, microbial and mucosal mRNA expression in bile acid diarrhoea and irritable bowel syndrome with diarrhoea [0.03%]
胆汁酸腹泻和腹泻型肠易激综合症的生化、微生物及粘膜mRNA表达比较分析
Michael Camilleri,Paula Carlson,Joelle BouSaba et al.
Michael Camilleri et al.
Objective: There are altered mucosal functions in irritable bowel syndrome with diarrhoea (IBS-D); ~30% of patients with IBS-D have abnormal bile acid (BA) metabolism (ABAM) and diarrhoea (summarised as BAD). ...
Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions [0.03%]
胆管癌生物标志物的临床意义：批判性回顾和未来方向
Rocio I R Macias,Vincenzo Cardinale,Timothy J Kendall et al.
Rocio I R Macias et al.
Cholangiocarcinoma (CCA) is a malignant tumour arising from the biliary system. In Europe, this tumour frequently presents as a sporadic cancer in patients without defined risk factors and is usually diagnosed at advanced stages with a cons...